rs1060502581 — BMPR2

BMPR2 R321* — A Silenced Receptor and the Quiet Onset of Pulmonary Hypertension

The blood vessels that carry blood from the right heart through the lungs depend on a protein called BMPR2¹¹ BMPR2
Bone Morphogenetic Protein Receptor Type 2 — a cell-surface kinase receptor on pulmonary vascular endothelial and smooth muscle cells that relays anti-proliferative BMP signals into the cell nucleus, restraining abnormal vascular wall growth to suppress abnormal muscle growth in the pulmonary artery walls. When this receptor is absent or defective, the tiny arteries in the lungs slowly narrow and stiffen — a process called pulmonary arterial hypertension (PAH) — forcing the right ventricle to pump against ever-increasing resistance until it fails. The BMPR2 c.961C>T variant (p.Arg321Ter) replaces the codon for arginine at position 321 with a premature stop signal, truncating the protein in the middle of its kinase domain and eliminating it through nonsense-mediated mRNA decay²² nonsense-mediated mRNA decay
NMD — a cellular surveillance mechanism that degrades mRNAs containing premature stop codons before they can be translated into truncated and potentially toxic proteins. Activation of NMD leaves only the intact allele to produce functional BMPR2. (NMD).

BMPR2 pathogenic variants are the most common hereditary cause of PAH, accounting for over 75% of familial PAH cases and approximately 15–25% of apparently sporadic (idiopathic) cases. The R321* stop-gain is classified Pathogenic in ClinVar (RCV000461193), supported by two independent clinical genetics laboratories, with the condition Pulmonary hypertension, primary, 1 (PPH1).

The Mechanism

BMPR2 encodes a transmembrane receptor that, when activated by bone morphogenetic protein (BMP) ligands, phosphorylates intracellular SMAD proteins and restrains the proliferation of pulmonary arterial smooth muscle cells. The Arg321 residue falls within the catalytic kinase domain; truncation at this position destroys the entire kinase module. NMD degrades the mutant transcript, leaving the single intact allele — a state of haploinsufficiency³³ haploinsufficiency
Having only one functional copy of a gene when two copies are normally required for adequate gene product. For BMPR2, one copy produces roughly half the normal receptor density, which is insufficient to maintain normal pulmonary vascular homeostasis in some individuals..

Truncating mutations escape the dominant-negative mechanism⁴⁴ Truncating mutations escape the dominant-negative mechanism
Unlike missense BMPR2 variants that produce a malfolded protein capable of poisoning the normal receptor, NMD-positive truncating mutations leave only haploinsufficiency. This is why truncating BMPR2 mutation carriers develop PAH later (typically after age 36) and with less severe hemodynamics than missense carriers, whose abnormal protein actively disrupts signaling. seen with missense variants. This predicts that R321* carriers, when they do develop disease, tend to present at older ages and with less extreme hemodynamic compromise — though the risk of death or transplantation remains substantially elevated once PAH is established.

The Evidence

Survival impact: The largest available data come from an individual participant data meta-analysis of 1,550 PAH patients⁵⁵ individual participant data meta-analysis of 1,550 PAH patients
Evans JDW et al., Lancet Respir Med, 2016 — pooled data from 8 cohorts; 448 (29%) carried any BMPR2 pathogenic variant; analysis adjusted for age and sex at diagnosis. BMPR2 mutation carriers had a 42% higher hazard of death or lung transplantation (HR 1.42, 95% CI 1.15–1.75) and 27% higher all-cause mortality (HR 1.27) than non-carriers. Carriers presented at a mean age of 35.4 years vs 42.0 years in non-carriers, and showed lower vasodilator responsiveness (3% vs 16%).

Truncating vs missense distinction: Austin et al., Respiratory Research, 2009⁶⁶ Austin et al., Respiratory Research, 2009
Compared hemodynamic profiles, age at diagnosis, and survival in 169 HPAH patients stratified by mutation type; truncating mutations spanned all ages while missense mutations clustered before age 36 — the age-based distinction supports NMD as protective against the most severe early-onset disease showed that carriers of truncating mutations (like R321*) develop PAH later and with milder hemodynamics than missense carriers, consistent with haploinsufficiency rather than dominant negative disruption.

Screening in asymptomatic carriers: The DELPHI-2 study⁷⁷ DELPHI-2 study
Montani D et al., Eur Respir J 2021; 55 asymptomatic adults carrying BMPR2 mutations enrolled prospectively; annual multimodal screening protocol; all detected PAH cases were low-risk at identification followed 55 asymptomatic BMPR2 carriers prospectively. Annual PAH incidence was 2.3% overall — 0.99% per year in males and 3.5% per year in females, consistent with the known sex-dependent penetrance. Cases identified by screening were all at low-risk stage and responded well to oral therapy — demonstrating that surveillance enables early, effective treatment.

Penetrance and sex dimorphism: Lifetime risk of developing PAH with a BMPR2 pathogenic variant is approximately 14% in males and 42% in females. The reason females have higher penetrance is not fully understood but may involve hormonal regulation of pulmonary vascular tone and BMPR2 expression.

Practical Actions

Identifying an R321* carrier before PAH develops is the key clinical opportunity: the DELPHI-2 study demonstrated that screening-detected cases are at low-risk and treatable with oral monotherapy, whereas symptomatic cases typically present with more advanced disease. Annual echocardiographic screening is the minimum standard; right heart catheterization is indicated when screening detects elevated pulmonary pressure estimates or symptoms.

Each first-degree biological relative has a 50% chance of inheriting the R321* variant. Cascade genetic testing identifies relatives who need surveillance before symptoms develop.

Interactions

The companion BMPR2 variant rs1060502576 (also in this batch) tags a distinct mutation in the same gene via the same haploinsufficiency mechanism. Compound heterozygosity for two BMPR2 loss-of-function alleles would be expected to cause more severe or earlier-onset PAH, though documented compound BMPR2 heterozygotes are extremely rare. Other PAH-associated genes — ACVRL1 (ALK1), ENG (endoglin), SMAD9, CAV1, KCNK3 — interact with the same BMP-SMAD signaling pathway and can modify penetrance. Carriers with additional risk factors (female sex, oral contraceptive use, anorexigens, portal hypertension, HIV) have meaningfully higher lifetime risk of clinical PAH expression.